Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.31 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL6805147 | 1.00 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL27681989 | 0.94 | CYP3A4 (0.40) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL342891 | 0.94 | CYP3A4 (0.40) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL342892 | 0.94 | CYP3A4 (0.40) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL28650960 | 0.93 | CYP3A4 (0.40) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL27729896 | 0.89 | CYP3A4 (0.37) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL28888007 | 0.89 | CYP3A4 (0.37) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL23362634 | 0.88 | BHMT (0.39) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 | |
| Histidine SCHEMBL28942432 | 0.88 | FNTA (0.38) | SLC7A5CYP3A4PTGS1 | |
| Histidine SCHEMBL23362032 | 0.88 | CYP1A2 (0.42) | SLC7A5CYP3A4CYP1A2GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246255-A1 | Stable Analogs of Peptide and Polypeptide Therapeutics | BACH BIOSCIENCES, LLC | 2017-08-31 | — | — | US | claimed |
| CN-102174102-A | Stable analogs of peptide and polypeptide therapeutics | TUFTS COLLEGE | 2011-09-07 | — | — | CN | claimed |
| US-7414107-B2 | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis | ZEALAND PHARMA A/S (DK) | 2008-08-19 | — | — | US | claimed |
| US-20080139785-A1 | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis | LARSEN BJARNE DUE | 2008-06-12 | — | — | US | claimed |
| CN-1822851-A | Stable analogs of peptide and polypeptide drugs | TUFTS COLLEGE (US) | 2006-08-23 | — | — | CN | claimed |
| US-20060063699-A1 | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis | LARSEN BJARNE D | 2006-03-23 | — | — | US | claimed |
| EP-1633384-A2 | STABLE ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | Trustees of Tufts College (US) | 2006-03-15 | — | — | EP | claimed |
| US-6969702-B2 | Compounds and methods for increasing neurogenesis | NEURONOVA AB (SE) | 2005-11-29 | — | — | US | claimed |
| US-20050049177-A1 | Stable analogs of peptide and polypeptide therapeutics | TRUSTEES OF TUFTS COLLEGE (US) | 2005-03-03 | — | — | US | claimed |
| WO-2004103390-A2 | STABLE ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2004-12-02 | — | — | WO | claimed |
| EP-1358485-A2 | METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2002035240-A2 | METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-05-02 | — | — | WO | claimed |
| EP-1062229-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | Zealand Pharmaceuticals A/S (DK) | 2000-12-27 | — | — | EP | claimed |
| WO-1999046283-A9 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A S (DK) | 1999-11-18 | — | — | WO | claimed |
| WO-1999046283-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1999-09-16 | — | — | WO | claimed |
| US-20230125604-A1 | ANTI-PACAP ANTIBODIES AND USES THEREOF | H LUNDBECK AS (DK) | 2023-04-27 | — | — | US | disclosed |
| CN-109311977-B | Humanized anti-PACAP antibodies and uses thereof | H.伦德贝克公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2000055184-A1 | ION EXCHANGE CHROMATOGRAPHY OF PROTEINS AND PEPTIDES WITH AN ORGANIC MODIFIER IN THE ELUTION STEP | NOVO NORDISK A/S (DK) | 2000-09-21 | — | — | WO | disclosed |
| WO-1999046283-A9 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A S (DK) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999046283-A1 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049177-A1 | Stable analogs of peptide and polypeptide therapeutics | IAPP, VIP, PREP | SLC7A5 2762/4885CYP3A4 4474/4885CYP1A2 4862/4885 |
| US-20170246255-A1 | Stable Analogs of Peptide and Polypeptide Therapeutics | IAPP, VIP, PREP | SLC7A5 2762/4885CYP3A4 4474/4885CYP1A2 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.